Similar Posts
Why should you include Genpact Ltd. (XNYS:G) in your portfolio?
Genpact Ltd. (NYSE: G) is a global professional services firm headquartered in New York City, with a significant international presence. Established in 1997 as a subsidiary of General Electric (GE), Genpact was originally known as GE Capital International Services. In 2005, the company was spun off from GE, adopting the name Genpact
Genpact’s analytics services turn data into actionable insights, empowering enterprises to make decisions at speed. They offer a range of analytics solutions across industries and functions that help teams make strategic, real-time decisions. With their data, technology, AI services, and digital operations, they fuse real-world expertise and collaborative innovation to make businesses work better.
TC Energy Corporation (TSX: TRP): Navigating the Energy Landscape with Strategic Growth and Resilience
TC Energy Corporation (TSX: TRP), based in Calgary, Alberta, is a leading North American energy company primarily involved in natural gas pipelines, liquids pipelines, and energy production. It operates one of the continent’s largest natural gas pipeline networks, spanning Canada, the U.S., and Mexico, while also managing a liquids pipeline system that includes the well-known Keystone Pipeline. Additionally, TC Energy has interests in power generation and storage, with assets in nuclear, natural gas, and hydroelectric power. The company is recognized for its stable financial performance, largely driven by long-term contracts and regulated assets, which provide predictable cash flows and support its regular dividend payments.
Tilray Brands, Inc.: How Craft Beer and Spirits Acquisitions Saved the Company’s Balance Sheet
Company Overview Ticker: TLRY(NASDAQ) Headquarters: New York, USA Founded: 2018 CEO: Irwin David Simon Industry: Agricultural Commodities Core Business Cannabis Tilray is the leading cannabis company in Canada and maintains a strong presence in the European medical cannabis market. Key…This report is available to MarketFacts members.Log in to read this report
Oil Demand Resilience Despite Renewable Push
The global energy transition is accelerating. Renewable capacity additions are reaching record levels, electric vehicle adoption is expanding, and governments are committing trillions toward decarbonization. Yet, despite this push, global oil demand remains resilient — and in many regions, continues to grow.
NVIDIA Corporation (NASDAQ: NVDA): Pioneering the Future of AI, Graphics, and High-Performance Computing
NVIDIA Corporation (NASDAQ: NVDA), founded in 1993 and headquartered in Santa Clara, California, is a leading technology company recognized for its graphics processing units (GPUs) and advanced computing technologies. Under the leadership of CEO Jensen Huang, NVIDIA has become a pivotal player in various sectors, including gaming, professional visualization, data centers, automotive, and AI. The company’s GeForce line of consumer GPUs is widely acclaimed in the gaming industry, while its GPUs also play a crucial role in data centers, supporting AI, deep learning, and high-performance computing (HPC) applications.
Arbutus Biopharma Corporation (NASDAQ: ABUS): Arbutus Biopharma’s Strategy in Biotechnology
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company headquartered in Warminster, Pennsylvania, focused on developing innovative therapies to treat chronic hepatitis B virus (HBV) infection. The company aims to achieve a functional cure for HBV by targeting multiple stages of the virus lifecycle through a combination of RNA interference (RNAi) therapies, capsid inhibitors, immune modulators, and HBV RNA destabilizers. Its lead product candidates include AB-729, an RNAi therapeutic designed to reduce hepatitis B surface antigen (HBsAg), and AB-836, a capsid inhibitor. Leveraging proprietary lipid nanoparticle (LNP) technology for RNA-based therapies, Arbutus is also engaged in collaborations to advance its pipeline. Arbutus is strategically positioned in the biopharmaceutical landscape, aiming to address unmet medical needs in HBV treatment. By pursuing a comprehensive approach that integrates cutting-edge science and collaboration, Arbutus continues to advance its pipeline and work toward transformative solutions for HBV patients globally.